Avatrombopag

COMPOSITION:

EACH FILM-COATED LUCITRAM TABLET CONTAINS: Avatrombopag maleate 23.6mg equivalent to avatrombopag 20mg

INDICATION:

LuciAvat is a thrombopoietin receptor agonist indicated for the treatment of:

· Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

· Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

DOSAGE AND USE:

1. Chronic Liver Disease: Dose LuciAvat based upon platelet count prior to procedure, orally for 5 days beginning 10 to 13 days before procedure. For platelet count less than 40 × 10 9/L, the dose is 60 mg (3 tablets) once daily; for platelet count 40 to less than 50 × 10 9/L, the dose is 40 mg (2 tablets) once daily.

2. Chronic Immune Thrombocytopenia: Initiate LuciAvat at 20 mg (1 tablet) once daily. Adjust the dose or frequency of dosing to maintain platelet count greater than or equal to 50 × 10 9 /L.

Do not exceed 40 mg per day.

Tablets should be swallowed whole & not chewed or crushed and with food.

STORAGE:

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.